Publication at First Faculty of Medicine |
2014
Abstract
Cabazitaxel has been shown to prolong survival versus mitoxantrone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel. We report two cases of patients with metastatic castration-resistant prostate cancer who were treated with cabazitaxel.